Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer.
Asian American lineage
Asian lineage
E6350
European variant
HPV vaccine
HPV16 variants
cervical cancer
genotyping
human papillomavirus
young women
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
13 Mar 2023
13 Mar 2023
Historique:
received:
15
01
2023
revised:
25
02
2023
accepted:
06
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and HPV16 variants in biopsies from women ≤ 25 years of age with cervical carcinoma (CC) (cases), compared with those aged >25 years (controls), in a pre-vaccination cohort. HPV genotyping of archival paraffin blocks ( HPV16 was the commonest genotype in cases (54.5%, 12/22) and controls (66.7%, 46/69) ( Virological factors may account for the differences in CCs observed in younger compared with older women. All CCs in young women in this study had preventable 9vHPV types, which is important messaging for health provider adherence to new cervical screening guidelines.
Sections du résumé
BACKGROUND
BACKGROUND
In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and HPV16 variants in biopsies from women ≤ 25 years of age with cervical carcinoma (CC) (cases), compared with those aged >25 years (controls), in a pre-vaccination cohort.
METHODS
METHODS
HPV genotyping of archival paraffin blocks (
RESULTS
RESULTS
HPV16 was the commonest genotype in cases (54.5%, 12/22) and controls (66.7%, 46/69) (
CONCLUSIONS
CONCLUSIONS
Virological factors may account for the differences in CCs observed in younger compared with older women. All CCs in young women in this study had preventable 9vHPV types, which is important messaging for health provider adherence to new cervical screening guidelines.
Identifiants
pubmed: 36986373
pii: pathogens12030451
doi: 10.3390/pathogens12030451
pmc: PMC10051959
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Health and Medical Research Council
ID : 568971
Organisme : Victorian Cancer Agency
ID : Tumour Project Grant
Organisme : Cancer Council Victoria
ID : PhD Scholarship
Organisme : Royal Australian and New Zealand College of Obstetricians and Gynaecologists
ID : PhD Scholarship
Organisme : Royal Australasian College of Physicians
ID : Novartis Scholarship
Références
J Virol. 1997 Mar;71(3):2463-72
pubmed: 9032384
J Virol. 1993 Nov;67(11):6424-31
pubmed: 8411344
N Engl J Med. 2007 May 10;356(19):1928-43
pubmed: 17494926
Aust N Z J Obstet Gynaecol. 2021 Jun;61(3):416-423
pubmed: 33512715
Vaccine. 2020 Sep 11;38(40):6312-6319
pubmed: 32736939
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
J Virol. 1992 Apr;66(4):2057-66
pubmed: 1312620
J Clin Microbiol. 2010 Apr;48(4):1458-60
pubmed: 20181920
Int J Cancer. 2017 Oct 15;141(8):1576-1584
pubmed: 28677147
Gynecol Oncol. 2022 Sep 20;:
pubmed: 36150914
J Med Virol. 2022 Feb;94(2):745-751
pubmed: 34569642
Virology. 2013 Oct;445(1-2):232-43
pubmed: 23998342
J Virol. 1993 Nov;67(11):6413-23
pubmed: 8411343
J Womens Health (Larchmt). 2016 Nov 17;26(7):774-787
pubmed: 27854558
Virology. 2001 Jan 5;279(1):361-9
pubmed: 11145917
J Clin Virol. 2016 Mar;76 Suppl 1:S81-S87
pubmed: 26651602
J Pathol. 2012 May;227(1):62-71
pubmed: 22127961
Virology. 2009 Aug 1;390(2):261-7
pubmed: 19497607
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Prev Med Rep. 2022 Nov 30;31:102070
pubmed: 36471770
J Clin Virol. 2016 Mar;76 Suppl 1:S74-S80
pubmed: 26589584
J Virol. 1995 Dec;69(12):7743-53
pubmed: 7494284
Int J Gynecol Cancer. 2006 May-Jun;16(3):1017-24
pubmed: 16803479
J Clin Virol. 2019 Oct;119:24-30
pubmed: 31446251
Aust N Z J Public Health. 2014 Oct;38(5):419-23
pubmed: 24962721
Antiviral Res. 2016 Jun;130:101-9
pubmed: 27040313